In terms of infections, as CD38 is expressed at the surface of activated CD4+T cells, this study cannot rule out that daratumumab might have played a role in predisposing patients to infections, such as pneumocystis or viral infections [16, 17]. The gene discussed is CD38; the disease is pneumocystosis.